Olympian Clinical Research

AUGUST 19, 2022

About one-third of people with psoriasis develop it during childhood, and pediatric psoriasis may appear as early as infancy. About 30% of children with eczema have a food allergy, and many children may develop asthma or hay fever. Insomnia, allergies, and asthma may also be more common in children with eczema.

Clinical Research 52

Clinical Research Allergies Doctors Doctor 52

The Pharma Data

FEBRUARY 5, 2021

American Society for Dermatologic Surgery (ASDS) consumer survey on cosmetic dermatologic procedures 2018 available at [link]. At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. N= 3,525 total study population. About Allergan Aesthetics.

Dermatology 52

Dermatology Cosmetics Allergies Production 52

Scienmag

MARCH 29, 2021

New review shows available psoriasis treatments differ in terms of how they affect a patient’s likelihood of experiencing adverse cardiovascular events Credit: Estzer Miller on Pixabay Psoriasis is a chronic disease that causes patients to develop patches of dry, scaly, and itchy skin.

Development 55

Development Dermatology Allergies Genetics 55

The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. The performance remained ahead of competition with growth momentum in the Dermatology and Nutritionals categories, with business up by 6.6

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

DECEMBER 30, 2020

billion acquisition of Germany-based Myr GmbH, a company focused on developing therapies for treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis. AstraZeneca Dives into Rare Diseases: AstraZeneca has been in the spotlight for the COVID-19 vaccine candidate it developed with Oxford University.

Antibody 52

Antibody Allergies Branding Dermatology 52

The Pharma Data

APRIL 28, 2021

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

pharmaphorum

SEPTEMBER 29, 2022

Development in peanut allergy has also been discontinued, said Sanofi in its second-quarter update. The post FDA clears Dupixent as first drug for rare skin disorder appeared first on.

Drugs 69

Drugs Immune Response Allergies Sales 69

The Pharma Data

JULY 8, 2021

Tezepelumab is being developed by AstraZeneca in collaboration with Amgen. Tezepelumab has demonstrated reductions in exacerbations irrespective of blood eosinophil counts, allergy status and fractional exhaled nitric oxide, and has the potential to transform treatment for a broad population of severe asthma patients.”.

Trials 52

Trials Medicine Sales Clinical Trials 52

The Pharma Data

SEPTEMBER 9, 2021

PT027 is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an inhaled corticosteroid (ICS), being developed by AstraZeneca and Avillion. 2 Inflammation is a distinctive feature of asthma 3 and plays a key role in asthma symptoms, 4 exacerbations 5 and deaths.

Trials 52

Trials Medicine Allergies Dermatology 52

The Pharma Data

APRIL 13, 2022

“I’m pleased that TAKHZYRO has met these key objectives and I look forward to Takeda sharing further insights with the HAE community in the near future,” said Dr. Marcus Maurer, Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin, Germany and principal investigator of SHP643-301.

Dermatology 52

Dermatology Allergies Genetics Antibody 52

Bioengineer

JULY 20, 2021

We look forward to partnering with patient organizations and the medical community to develop educational and other support programs that will serve dermatomyositis patients.” . “Octapharma is committed to providing life-saving and life-enhancing therapies for patients with rare diseases.

FDA Approval 40

FDA Approval Clinical Trials Clinical Trials Trials 40

XTalks

DECEMBER 20, 2023

These advancements and trends addressed important industry challenges and offered opportunities to foster innovations and solutions in areas including drug development, healthcare and medical devices. Bayer’s Astepro (azelastine), an over-the-counter medication for cold, flu and allergies, led the pack in the first half of 2023 with 7.4

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JANUARY 24, 2021

Gritstone Oncology , based in Emeryville, California, announced that it is advancing development of its own second-generation vaccine against COVID-19. It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. Read on to see. COVID-19-Related.

Trials 52

Trials Allergies In-Vitro Antibody 52

XTalks

JANUARY 2, 2025

Stelara (Ustekinumab) Stelara 2023 sales: $10.858 billion Company/developer: Johnson & Johnson Date of first FDA approval: September 25, 2009 Indications Stelara is FDA-approved for: Plaque psoriasis, psoriatic arthritis, Crohns disease and ulcerative colitis. In addition, AbbVie continues to invest in research and development.

Sales 85

Sales FDA Approval Drugs Marketing 85